国产与进口奥沙利铂治疗晚期结直肠癌的临床疗效和药物经济学评价

Efficacy and Pharmacoeconomic Evaluatation of Domestic vs. Imported Oxaliplatin in the Treatment of Advanced Colorectal Cancer

目的比较国产与进口奥沙利铂治疗晚期结直肠癌的疗效和药物经济学。方法将74例采用FOLFOX4化疗的晚期结直肠癌患者分为国产奥沙利铂A组(艾恒,n=23)和B组(齐沙,n=26)、进口奥沙利铂C组(乐沙定,n=25),观察国产与进口奥沙利铂的近期疗效和不良反应,并用最小成本分析法进行药物经济学研究。结果 A组、B组和C组治疗晚期结直肠癌的疗效与不良反应的差异均无统计学意义(P>0.05),化疗1个周期的成本分别为2704.74元、2604.04元、12 573.11元。结论国产与进口奥沙利铂对晚期结直肠癌的近期疗效和安全性相似,国产奥沙利铂药物经济学优于进口奥沙利铂。

Objective To evaluate the efficacy and pharmacoeconomics of domestic and imported oxaliplatin in the treatment of advanced colorectal cancer. Methods Seventy-four patients with advanced colorectal cancer were assigned to group A （domestic oxaliplatin named Aiheng, n=23）, group B （domestic oxaliplatin named Qisha, n=26） and group C （imported oxaliplatin named Eloxatin, n=25）. Their efficacy was evaluated and adverse reactions were observed. Cost minimization analysis was applied to evaluate their pharmacoeconomics. Results There were no statistical significances in efficacy and adverse reactions between the three groups （P〉 0.05）. The cost per chemotherapeutic cycte was 2704.74 Yuan, 2604.04 Yuan and 12 573.11 Yuan respectively in group A, B and C. Conclusion The results indicated that do- mestic oxaliplatin had a similar short-term efficiency and safety with imported oxaliplatin for advanced colorectal cancer patients, but it was a more affordable option than imported oxaliplatin.